Delcath Systems, Inc.
Status: Publicly traded
Direct answer
Delcath Systems, Inc. is publicly traded on NASDAQ under the ticker DCTH.
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug...
Can you invest in Delcath Systems, Inc.?
Yes. Delcath Systems, Inc. trades publicly on NASDAQ as DCTH.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Delcath Systems, Inc.
Detailed equity research is provided by MarketSnap.